
Turning Point Therapeutics TPTX
Quarterly report 2022-Q2
added 08-08-2022
Turning Point Therapeutics Operating Expenses 2011-2026 | TPTX
Annual Operating Expenses Turning Point Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 269 M | 187 M | 77.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 269 M | 77.7 M | 178 M |
Quarterly Operating Expenses Turning Point Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 124 M | 75.4 M | - | 67.1 M | 61.8 M | 61.3 M | - | 43.5 M | 32.7 M | 62.6 M | - | 22.1 M | 18.5 M | 14.1 M | - | 6.13 M | 5.17 M | 4.86 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | 4.86 M | 42.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
94.5 M | $ 3.44 | 2.99 % | $ 303 M | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 218.06 | -1.72 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Amgen
AMGN
|
9.33 B | $ 349.77 | 0.57 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.23 | -1.38 % | $ 899 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Amarin Corporation plc
AMRN
|
171 M | $ 14.6 | 0.76 % | $ 6.06 B | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Inventiva S.A.
IVA
|
36.2 M | $ 6.08 | 5.19 % | $ 138 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.4 | 2.19 % | $ 357 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.63 | 0.77 % | $ 16.5 M | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | ||
|
Benitec Biopharma
BNTC
|
9.83 M | $ 11.19 | 1.91 % | $ 461 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.42 | 4.25 % | $ 734 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Cabaletta Bio
CABA
|
172 M | $ 2.82 | -4.08 % | $ 3.29 M | ||
|
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M |